Liver Cancer Trial, Recruiting (NCT05828446)

Liver Cancer Trial, Recruiting NCT05828446 Sponsor: Naik Vietti Violi Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05828446 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults who have a chronic liver disease and who meet the European liver disease guidelines for regular liver cancer screening.
People who have signed an informed consent form agreeing to take part in the study.

Who may not be able to join:

People who have previously been diagnosed with liver cancer (HCC).
People who have a history of any other type of cancer.
People who have previously had a liver nodule (growth) classified as a high-risk or suspicious category on a liver imaging scan (known as LI-RADS category 4, 5, or M) (confirm with trial site).
People who have had a liver transplant in the past.
People who are pregnant.
People for whom an MRI scan or the contrast dye used during an MRI is not considered safe (confirm with trial site).
People who have any other condition that the trial team considers would make participation unsuitable.
People who are not willing to allow relevant medical findings from study examinations to be shared as part of the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Naik Vietti Violi, MD, University of Lausanne Hospitals

Phone: +41213144556

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05828446

Sponsor: Naik Vietti Violi

Phase: Not Applicable

Status: Recruiting

Condition: Liver Cancer

Trial contact: +41213144556

More information: https://clinicaltrials.gov/study/NCT05828446

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults who have a chronic liver disease and who meet the European liver disease guidelines for regular liver cancer screening.
People who have signed an informed consent form agreeing to take part in the study.

Who may not be able to join:

People who have previously been diagnosed with liver cancer (HCC).
People who have a history of any other type of cancer.
People who have previously had a liver nodule (growth) classified as a high-risk or suspicious category on a liver imaging scan (known as LI-RADS category 4, 5, or M) (confirm with trial site).
People who have had a liver transplant in the past.
People who are pregnant.
People for whom an MRI scan or the contrast dye used during an MRI is not considered safe (confirm with trial site).
People who have any other condition that the trial team considers would make participation unsuitable.
People who are not willing to allow relevant medical findings from study examinations to be shared as part of the study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Naik Vietti Violi

Registry

ClinicalTrials.gov

Start date

1 April 2023

Est. completion

30 April 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

To compare the diagnostic performance of US+/- CEUS and AMRI for HCC detection in an at-risk population

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov